Tolebrutinib
A medication under investigation for multiple sclerosis and other autoimmune diseases
| Tolebrutinib | |
|---|---|
[[File: | |
| INN | |
| Drug class | |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | 1971929-97-7 |
| PubChem | 129073382 |
| DrugBank | |
| ChemSpider | 68012192 |
| KEGG | D11792 |
Overview[edit]
Tolebrutinib is an investigational Bruton tyrosine kinase (BTK) inhibitor being developed for the treatment of multiple sclerosis (MS) and other autoimmune diseases. It is designed to modulate the immune system by inhibiting the activity of BTK, a key enzyme involved in the signaling pathways of B cells and myeloid cells.
Mechanism of Action[edit]
Tolebrutinib works by selectively inhibiting BTK, which plays a crucial role in the activation and function of B cells and other immune cells. By blocking BTK, tolebrutinib aims to reduce the abnormal immune response that characterizes autoimmune diseases such as multiple sclerosis. This inhibition can potentially decrease the inflammation and damage to the nervous system seen in MS.
Clinical Development[edit]
Tolebrutinib is currently undergoing clinical trials to evaluate its safety and efficacy in patients with multiple sclerosis. These trials are designed to assess the drug's ability to reduce the frequency of relapses and slow the progression of disability in MS patients. The drug is administered orally, which may offer a convenient alternative to injectable therapies currently available for MS.
Potential Indications[edit]
While the primary focus of tolebrutinib's development is for the treatment of multiple sclerosis, its mechanism of action suggests potential applications in other autoimmune diseases. The inhibition of BTK could be beneficial in conditions where B cells and myeloid cells play a significant role in disease pathology.
Safety and Tolerability[edit]
The safety profile of tolebrutinib is being closely monitored in clinical trials. As with any investigational drug, potential side effects and adverse reactions are being evaluated to ensure the drug's safety for future use in patients.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
